Purpose: To describe the clinical features and to analyze BEST1 mutations in patients with Best vitelliform macular dystrophy (BVMD). Methods: Thirteen individuals affected by BVMD from 6 unrelated Chinese families were studied. Complete ophthalmological examinations were performed, and the BEST1 gene was screened in all participants and 100 controls. Follow-ups were arranged within 12 months. Results: All 6 probands showed typical fundus appearances of BVMD. One of the 6 had a history of angle closure glaucoma, and another showed a unilateral focal choroidal excavation on optical coherence tomography. One patient experienced progression of the macular lesion during the follow-up. The asymptomatic mutation carriers had normal fundus but abnormal Arden ratios on electro-oculograms. Besides 4 previously reported mutations (p.Ser16Phe, p.Ser144Asn, p.Glu292Lys, p.Glu300Lys), 2 novel disease-causing mutations (p.Thr307Asp, p.Arg47His) were identified, of which p.Arg47His has been reported in adult-onset vitelliform macular dystrophy. Conclusions: Our findings have expanded the mutational and clinical spectrum of BVMD in a Chinese population. Clinical presentations of angle closure glaucoma and/or focal choroidal excavation may be related to BVMD, underlining the necessity of multimodal studies and risk assessment of angle closure glaucoma in BEST1 mutation carriers. BVMD and adult-onset vitelliform macular dystrophy may share a common etiology in some cases.

1.
Boon CJ, Klevering BJ, Leroy BP, Hoyng CB, Keunen JE, den Hollander AI: The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 2009;28:187-205.
2.
Mohler CW, Fine SL: Long-term evaluation of patients with Best's vitelliform dystrophy. Ophthalmology 1981;88:688-692.
3.
Meunier I, Senechal A, Dhaenens CM, Arndt C, Puech B, Defoort-Dhellemmes S, Manes G, Chazalette D, Mazoir E, Bocquet B, Hamel CP: Systematic screening of BEST1 and PRPH2 in juvenile and adult vitelliform macular dystrophies: a rationale for molecular analysis. Ophthalmology 2011;118:1130-1136.
4.
Meunier I, Manes G, Bocquet B, Marquette V, Baudoin C, Puech B, Defoort-Dhellemmes S, Audo I, Verdet R, Arndt C, Zanlonghi X, Le Meur G, Dhaenens CM, Hamel CP: Frequency and clinical pattern of vitelliform macular dystrophy caused by mutations of interphotoreceptor matrix IMPG1 and IMPG2 genes. Ophthalmology 2014;121:2406-2414.
5.
Tian R, Yang G, Wang J, Chen Y: Screening for BEST1 gene mutations in Chinese patients with bestrophinopathy. Mol Vis 2014;20:1594-1604.
6.
Wong RL, Hou P, Choy KW, Chiang SW, Tam PO, Li H, Chan WM, Lam DS, Pang CP, Lai TY: Novel and homozygous BEST1 mutations in Chinese patients with Best vitelliform macular dystrophy. Retina 2010;30:820-827.
7.
Margolis R, Mukkamala SK, Jampol LM, Spaide RF, Ober MD, Sorenson JA, Gentile RC, Miller JA, Sherman J, Freund KB: The expanded spectrum of focal choroidal excavation. Arch Ophthalmol 2011;129:1320-1325.
8.
Kramer F, White K, Pauleikhoff D, Gehrig A, Passmore L, Rivera A, Rudolph G, Kellner U, Andrassi M, Lorenz B, Rohrschneider K, Blankenagel A, Jurklies B, Schilling H, Schutt F, Holz FG, Weber BH: Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet 2000;8:286-292.
9.
Sun H, Tsunenari T, Yau KW, Nathans J: The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci USA 2002;99:4008-4013.
10.
Xiao Q, Prussia A, Yu K, Cui YY, Hartzell HC: Regulation of bestrophin Cl channels by calcium: role of the C terminus. J Gen Physiol 2008;132:681-692.
11.
Qu Z, Cheng W, Cui Y, Cui Y, Zheng J: Human disease-causing mutations disrupt an N-C-terminal interaction and channel function of bestrophin 1. J Biol Chem 2009;284:16473-16481.
12.
Lotery AJ, Munier FL, Fishman GA, Weleber RG, Jacobson SG, Affatigato LM, Nichols BE, Schorderet DF, Sheffield VC, Stone EM: Allelic variation in the VMD2 gene in best disease and age-related macular degeneration. Invest Ophthalmol Vis Sci 2000;41:1291-1296.
13.
Caldwell GM, Kakuk LE, Griesinger IB, Simpson SA, Nowak NJ, Small KW, Maumenee IH, Rosenfeld PJ, Sieving PA, Shows TB, Ayyagari R: Bestrophin gene mutations in patients with Best vitelliform macular dystrophy. Genomics 1999;58:98-101.
14.
Gass JD: A clinicopathologic study of a peculiar foveomacular dystrophy. Trans Am Ophthalmol Soc 1974;72:139-156.
15.
Renner AB, Fiebig BS, Weber BH, Wissinger B, Andreasson S, Gal A, Cropp E, Kohl S, Kellner U: Phenotypic variability and long-term follow-up of patients with known and novel PRPH2/RDS gene mutations. Am J Ophthalmol 2009;147:518-530 e511.
16.
Seddon JM, Afshari MA, Sharma S, Bernstein PS, Chong S, Hutchinson A, Petrukhin K, Allikmets R: Assessment of mutations in the Best macular dystrophy (VMD2) gene in patients with adult-onset foveomacular vitelliform dystrophy, age-related maculopathy, and bull's-eye maculopathy. Ophthalmology 2001;108:2060-2067.
17.
Low S, Davidson AE, Holder GE, Hogg CR, Bhattacharya SS, Black GC, Foster PJ, Webster AR: Autosomal dominant Best disease with an unusual electrooculographic light rise and risk of angle-closure glaucoma: a clinical and molecular genetic study. Mol Vis 2011;17:2272-2282.
18.
Wittstrom E, Ponjavic V, Bondeson ML, Andreasson S: Anterior segment abnormalities and angle-closure glaucoma in a family with a mutation in the BEST1 gene and Best vitelliform macular dystrophy. Ophthalmic Genet 2011;32:217-227.
19.
Sohn EH, Francis PJ, Duncan JL, Weleber RG, Saperstein DA, Farrell DF, Stone EM: Phenotypic variability due to a novel Glu292Lys variation in exon 8 of the BEST1 gene causing best macular dystrophy. Arch Ophthalmol 2009;127:913-920.
20.
Parodi MB, Zucchiatti I, Fasce F, Bandello F: Bilateral choroidal excavation in best vitelliform macular dystrophy. Ophthalmic Surg Lasers Imaging Retina 2014;45:e8-e10.
21.
Esfahani MR, Esfahani HR, Mahmoudi A, Johari MK, Hemati K: Focal choroidal excavation in Best vitelliform macular dystrophy: case report. J Clin Diagn Res 2015;9:ND01-ND02.
22.
Lee CS, Woo SJ, Kim YK, Hwang DJ, Kang HM, Kim H, Lee SC: Clinical and spectral-domain optical coherence tomography findings in patients with focal choroidal excavation. Ophthalmology 2014;121:1029-1035.
23.
Shinojima A, Kawamura A, Mori R, Yuzawa M: Morphologic features of focal choroidal excavation on spectral domain optical coherence tomography with simultaneous angiography. Retina 2014;34:1407-1414.
24.
Xu H, Zeng F, Shi D, Sun X, Chen X, Bai Y: Focal choroidal excavation complicated by choroidal neovascularization. Ophthalmology 2014;121:246-250.
25.
Jampol LM, Shankle J, Schroeder R, Tornambe P, Spaide RF, Hee MR: Diagnostic and therapeutic challenges. Retina 2006;26:1072-1076.
26.
Ellabban AA, Tsujikawa A, Ooto S, Yamashiro K, Oishi A, Nakata I, Miyake M, Akagi-Kurashige Y, Ueda-Arakawa N, Arichika S, Yoshitake S, Takahashi A, Yoshimura N: Focal choroidal excavation in eyes with central serous chorioretinopathy. Am J Ophthalmol 2013;156:673-683.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.